List of Excipients in Branded Drug IQIRVO

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Ipsen Biopharmaceuticals Inc	IQIRVO	elafibranor	15054-0080	CELLULOSE, MICROCRYSTALLINE	2031-06-10
Ipsen Biopharmaceuticals Inc	IQIRVO	elafibranor	15054-0080	CROSCARMELLOSE SODIUM	2031-06-10
Ipsen Biopharmaceuticals Inc	IQIRVO	elafibranor	15054-0080	FERRIC OXIDE RED	2031-06-10

IQIRVO Excipient Strategy and Commercial Opportunities

Last updated: September 18, 2026

IQIRVO (elafibranor) is an 80 mg oral tablet approved by the FDA for adults with primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) when the patient has an inadequate response to UDCA or as monotherapy when UDCA is not tolerated.[1] Its commercial formulation is a conventional immediate-release film-coated tablet taken once daily, with or without food.

The main excipient opportunities are generic or 505(b)(2) development, lactose-free reformulation, supply-chain diversification, and differentiated combination packaging with UDCA. The largest regulatory barriers are bioequivalence, inactive-ingredient justification, control of oxidative and physical stability, and potential formulation or method-of-use patent protection. IQIRVO has no biosimilar pathway because it is a small-molecule drug.

What is IQIRVO and how is it used?

IQIRVO contains elafibranor, a peroxisome proliferator-activated receptor alpha/delta agonist. It is indicated for adults with PBC who have not responded adequately to UDCA or who cannot tolerate UDCA.[1]

Attribute	IQIRVO profile
Active ingredient	Elafibranor
Strength	80 mg
Dosage form	Oral film-coated tablet
Administration	Once daily
Food requirement	May be taken with or without food
Primary indication	Primary biliary cholangitis
Combination use	With UDCA when response to UDCA is inadequate
Monotherapy	When UDCA is not tolerated
FDA approval	June 10, 2024
FDA pathway	Accelerated approval
Sponsor at approval	Ipsen Biopharmaceuticals
Original development partner	Genfit

The FDA approval was based on biochemical response data, including alkaline phosphatase reduction. Continued approval is contingent on verification of clinical benefit in confirmatory studies.[1][2]

What excipients are used in IQIRVO tablets?

The IQIRVO tablet uses standard oral solid-dose excipients rather than a complex delivery platform. Public labeling identifies a conventional matrix of fillers, disintegrants, lubricants, glidants, surfactants and film-coating materials.[1]

Reported inactive ingredients include:

• Colloidal silicon dioxide
• Croscarmellose sodium
• Hypromellose
• Lactose monohydrate
• Magnesium stearate
• Microcrystalline cellulose
• Polysorbate 80
• Sodium lauryl sulfate
• Talc
• Titanium dioxide
• Yellow iron oxide

The formulation suggests that IQIRVO does not depend on a modified-release polymer system, enteric coating, lipid vehicle or specialized absorption enhancer. This reduces manufacturing complexity but also lowers the formulation barrier to conventional generic competition.

What roles do IQIRVO’s excipients perform?

Excipient class	Likely function	Commercial relevance
Lactose monohydrate	Diluent and tablet-bulk agent	Creates an opportunity for lactose-free alternatives
Microcrystalline cellulose	Compressibility and structural support	Broad supplier base; low differentiation
Croscarmellose sodium	Tablet disintegration	Critical for dissolution and bioequivalence
Magnesium stearate	Lubrication during compression	Excess use can slow dissolution
Colloidal silicon dioxide	Flow improvement and moisture control	Supports consistent tablet manufacture
Polysorbate 80	Wetting or formulation aid	May require tight control of peroxide and degradation impurities
Sodium lauryl sulfate	Wetting and dissolution support	Can improve release from hydrophobic drug particles
Hypromellose and talc	Film-coating components	Affect coating performance and tablet appearance
Titanium dioxide and yellow iron oxide	Opacification and color	Supports product identification and brand differentiation

Elafibranor’s low daily dose relative to total tablet mass means excipient selection can materially affect tablet size, blend uniformity, dissolution, and manufacturability. The formulation must maintain consistent release despite changes in particle size, lubricant concentration, compression force and coating weight.

What excipient strategy is most attractive for IQIRVO?

The strongest strategy is a platform approach that preserves immediate release while improving manufacturability and patient acceptability.

Lactose-free formulation

IQIRVO contains lactose monohydrate according to public labeling. A lactose-free version could replace lactose with combinations of microcrystalline cellulose, mannitol, dibasic calcium phosphate or coprocessed excipients.

The commercial rationale is limited but clear:

• Reduce concerns among patients with lactose intolerance.
• Simplify use in markets where lactose declaration affects prescribing or patient counseling.
• Create a differentiated product for specialty pharmacies.
• Provide a second-source formulation if lactose supply or quality becomes constrained.

A lactose-free product would not automatically receive meaningful regulatory exclusivity. Its value would depend on formulation patents, a 505(b)(2) strategy, manufacturing advantages or commercial contracting.

Direct-compression formulation

A direct-compression platform could reduce granulation steps, solvent use and manufacturing cost. The formulation would need to manage:

• Elafibranor content uniformity.
• Powder flow.
• Segregation during high-speed compression.
• Magnesium-stearate sensitivity.
• Dissolution after scale-up.
• Tablet friability and coating adhesion.

A direct-compression generic may be commercially attractive if it achieves bioequivalence with fewer unit operations than the reference product. The cost advantage would be more important in large international markets than in the early U.S. specialty market.

Moisture and oxidative stability control

Polysorbate 80 and other formulation components can introduce peroxide or oxidation-related risks. A robust strategy would evaluate:

• Excipient peroxide specifications.
• Packaging moisture transmission.
• Oxygen exposure during blending and storage.
• Light protection.
• Compatibility of the active ingredient with surfactants and coating materials.
• Nitrogen purging or improved blister packaging where justified.

Alu-Alu blister packaging could provide stronger moisture and oxygen protection than standard high-density polyethylene bottles, although the incremental cost must be balanced against the stability data.

Smaller or easier-to-swallow tablets

PBC is a chronic disease requiring long-term treatment. Tablet burden and swallowability are commercially relevant, particularly for patients taking IQIRVO with UDCA and other chronic medicines.

Potential approaches include:

• Higher-density excipient systems.
• Reduced coating weight.
• Smaller tablet geometry.
• A scored tablet, if dose flexibility is clinically justified.
• A capsule or multiparticulate formulation.
• An orally disintegrating tablet, although taste masking and dose loading would be difficult.

A smaller tablet is more commercially realistic than an orally disintegrating product. IQIRVO’s 80 mg strength is suitable for conventional tablet compression, but reducing tablet size without compromising content uniformity and dissolution could require a substantially different formulation.

What formulation patents could protect IQIRVO alternatives?

The active ingredient and approved use may be protected by patents held by Ipsen, Genfit or related entities, but excipient-based claims would require a separate formulation invention. Potential claim categories include:

1. Specific elafibranor particle-size distributions.
2. Defined ratios of elafibranor to surfactant or disintegrant.
3. Low-peroxide excipient systems.
4. Lactose-free immediate-release tablets.
5. Stability-enhancing packaging combinations.
6. Fast-dissolving or reduced-size tablets.
7. Fixed-dose or co-packaged elafibranor and UDCA products.
8. Manufacturing processes that improve content uniformity or dissolution.

A formulation patent is stronger when it links a narrow composition to unexpected results, such as improved dissolution, reduced degradation, longer shelf life or improved bioavailability. Broad claims covering ordinary use of microcrystalline cellulose, lactose, croscarmellose sodium or magnesium stearate would face significant validity and obviousness risk.

When does IQIRVO lose exclusivity?

IQIRVO’s U.S. regulatory exclusivity is linked to its June 2024 approval and PBC orphan-drug status. Orphan-drug exclusivity generally lasts seven years from approval, which would place the expected U.S. orphan exclusivity endpoint in June 2031 if the designation and statutory conditions apply.[1][3]

Exclusivity element	IQIRVO assessment
FDA approval	June 10, 2024
Orphan-drug exclusivity	Expected to run through approximately June 2031
New chemical entity exclusivity	Potentially applicable, subject to FDA listing and calculation
Patent expiry	Must be assessed from issued claims and current Orange Book records
Pediatric exclusivity	No public basis in the cited sources for assigning six-month pediatric extension
Biosimilar exclusivity	Not applicable
Generic pathway	ANDA likely, subject to listed patents and exclusivity

Patent expiry cannot be inferred from FDA approval timing. The commercial entry date will depend on issued patent claims, Orange Book listings, Paragraph IV certifications, litigation and any settlement restrictions.

What is the Orange Book and Paragraph IV risk for IQIRVO?

IQIRVO is an FDA-approved small-molecule product eligible for Orange Book listing. Generic applicants may seek approval through an abbreviated new drug application and certify against listed patents.

A Paragraph IV challenge would assert that a listed patent is invalid, unenforceable or not infringed. The principal risk areas would likely include:

• Composition of matter claims for elafibranor.
• Salt, polymorph or solid-state claims.
• Tablet or formulation claims.
• Treatment claims for PBC.
• Combination-use claims involving UDCA.
• Manufacturing or impurity-control claims.

A Paragraph IV notice can trigger patent litigation and a potential 30-month stay of approval under the Hatch-Waxman framework, subject to statutory requirements.[4] A generic may also file a Paragraph III certification and wait for relevant patent expiry.

Because IQIRVO was approved recently, early commercial generic activity is more likely to focus on patent landscaping and formulation development than immediate launch. The most credible generic launch scenario would involve an ANDA with a non-infringing formulation, followed by launch after regulatory and patent barriers expire or are resolved.

What commercial opportunities exist for IQIRVO excipients?

Generic IQIRVO

The most direct opportunity is a conventional immediate-release generic. Key advantages would be:

• Low-cost excipient platform.
• Standard tablet equipment.
• Established suppliers.
• No biologic comparability requirement.
• Straightforward once-daily administration.

The principal commercial constraint is the size of the eligible PBC population. PBC is a rare disease, so revenue depends on pricing, market share, persistence and international access rather than prescription volume alone.

505(b)(2) reformulation

A reformulated product could use the 505(b)(2) pathway if it provides a meaningful difference from the reference product and the sponsor can rely partly on FDA findings for IQIRVO.[5]

Potential products include:

• Lactose-free IQIRVO.
• Smaller tablet.
• Improved stability formulation.
• Alternative dosage form.
• Modified-release product, although once-daily immediate release reduces the need.
• Combination product or coordinated package with UDCA.

A 505(b)(2) product must offer a defensible clinical, pharmaceutical or patient-use advantage. A cosmetic excipient substitution alone would have limited value.

IQIRVO-UDCA co-packaging

IQIRVO is used with UDCA in patients who have an inadequate response to UDCA. A co-pack could improve adherence and create a specialty-pharmacy offering. The opportunity has limitations:

• UDCA is widely available from multiple manufacturers.
• Dose requirements may vary by patient weight and prescribing practice.
• A co-pack may not qualify as a fixed-dose combination.
• Packaging would not necessarily create new drug exclusivity.
• Commercial success would depend on payer acceptance and reduced medication abandonment.

A fixed-dose combination tablet would face more complex development, because the dose ratio and food effect of each component would need to be characterized.

Excipient supplier opportunities

Excipient manufacturers can target IQIRVO-related development through:

• Direct-compression filler systems.
• Low-peroxide polysorbate 80.
• Coprocessed filler-disintegrant platforms.
• Lactose-free tablet bases.
• High-barrier blister systems.
• Film-coating systems that reduce processing time.
• Continuous manufacturing-compatible excipient blends.

The best supplier opportunity is a validated platform that reduces development risk across multiple elafibranor formulations, rather than a commodity excipient sold solely into the branded product.

How does IQIRVO compare with other PBC drugs?

IQIRVO competes primarily with UDCA and other PBC therapies, including obeticholic acid in markets where it remains available and investigational or approved alternatives depending on jurisdiction.

Product	Active ingredient	Formulation profile	Competitive implication
IQIRVO	Elafibranor	80 mg immediate-release tablet	Simple oral formulation; excipient differentiation is feasible
UDCA	Ursodeoxycholic acid	Multiple generic oral forms	Low cost and broad availability
Ocaliva	Obeticholic acid	Immediate-release tablet	Competes in PBC but has a different safety and regulatory history
Emerging PBC agents	Various	Oral and potentially advanced formulations	May compete through efficacy, tolerability or dosing convenience

IQIRVO’s formulation is less technically complex than injectable biologics or long-acting delivery systems. Its competitive strength therefore depends more on clinical positioning, safety, regulatory status, access and patent duration than on delivery technology.

What manufacturing and geographic barriers affect IQIRVO?

Manufacturing barriers are moderate. The drug uses standard oral solid-dose equipment, but commercial developers must control active-ingredient sourcing, solid-state properties, content uniformity and dissolution.

Geographic opportunities include:

• United States: highest value for an FDA-compliant generic or differentiated 505(b)(2) product.
• European Union: opportunity depends on centralized or national authorization, orphan status and national reimbursement.
• Japan: potential demand exists but requires local regulatory and commercial strategy.
• Emerging markets: lower pricing but greater opportunity for UDCA-IQIRVO co-packs and lactose-free presentations.

A global product should avoid excipients that create region-specific labeling, allergen or supply issues. Lactose, titanium dioxide, talc and sodium lauryl sulfate may require market-specific regulatory review or customer preferences, even when legally permitted.

How strong is the IQIRVO formulation estate?

The formulation estate appears technically moderate rather than highly complex. Conventional immediate-release tablets are generally easier to design around than controlled-release, depot or device-based products. The commercial strength of the estate will depend on whether issued patents claim the active ingredient, a specific solid form, the tablet composition, the treatment method or the manufacturing process.

For excipient-focused competitors, the highest-risk areas are likely active-ingredient and method-of-use patents, not routine excipient substitutions. A non-infringing lactose-free or direct-compression formulation could be commercially viable if it meets bioequivalence requirements and avoids valid listed claims.

Key Takeaways

• IQIRVO is an 80 mg once-daily immediate-release elafibranor tablet for PBC.
• Its excipient system is conventional and includes lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, surfactants and film-coating agents.
• The strongest formulation opportunities are lactose-free tablets, smaller tablets, direct compression, improved stability and high-barrier packaging.
• A conventional ANDA generic is the most direct commercial opportunity.
• A 505(b)(2) product needs a measurable advantage beyond ordinary excipient substitution.
• IQIRVO is a small molecule, so biosimilar risk does not apply.
• Expected U.S. orphan exclusivity could extend to approximately June 2031, subject to the applicable FDA designation and statutory calculation.
• Patent and Paragraph IV risk must be evaluated separately from FDA exclusivity.
• The limited PBC population favors premium specialty pricing, adherence programs, payer access and differentiated packaging over high-volume generic economics.

FAQs About IQIRVO Excipient and Commercial Strategy

Is IQIRVO lactose-free?

No. Public FDA labeling identifies lactose monohydrate as an inactive ingredient in IQIRVO tablets.[1]

Can a generic IQIRVO use different excipients?

Yes. An ANDA applicant generally may use different inactive ingredients if the formulation satisfies FDA requirements, including safety, quality, dissolution and bioequivalence standards.

Is an IQIRVO orally disintegrating tablet commercially attractive?

Potentially, but it would require proof of a meaningful patient or clinical advantage. Taste masking, dose loading, tablet robustness and stability would be central development issues.

Does IQIRVO need a special delivery device?

No. IQIRVO is administered as a conventional oral tablet and does not require an injector, inhaler, patch or drug-delivery device.

Could IQIRVO and UDCA be sold as a fixed-dose combination?

A co-pack is more straightforward than a fixed-dose tablet. A fixed-dose combination would require additional formulation, dose-ratio, stability, pharmacokinetic and regulatory work.

References

1. U.S. Food and Drug Administration. (2024). IQIRVO (elafibranor) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024, June 10). FDA grants accelerated approval to drug for adults with primary biliary cholangitis. FDA.

3. U.S. Food and Drug Administration. (2023). Orphan drug act: Relevant statutory and regulatory provisions. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.

5. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA.